AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

ABARELIX (Intramuscular route) - a-ba-REL-iks.(Drug overview)

USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language

| May 01, 2007 | COPYRIGHT 1996 USP DIĀ® and Advice for the PatientĀ® are registered trademarks of USP used under license to Micromedex, Inc. (Hide copyright information)Copyright

Dosage forms --

* Powder for Suspension

Therapeutic classification: Antineoplastic Agent

Pharmacologic classification: Luteinizing Hormone Releasing Hormone Antagonist

DESCRIPTION OF USE

Abarelix is a type of medicine called a gonadotropin-releasing hormone (GnRH) antagonist that lowers the male hormone testosterone in your blood. Testosterone makes most prostate cancers grow. Other ways to treat your prostate cancer are taking other hormone medicines to lower testosterone or surgery to remove your testicles. Abarelix is used when these other ways to treat prostate cancer cannot be used or are refused.

Abarelix is to be given only under the supervision of your doctor. It is to be injected into your buttocks.

This medicine was available only with your doctor's prescription.

This medicine was withdrawn from the U.S. market in May 2005, and is available only to patients who are currently receiving the medicine .

BEFORE USING THIS MEDICINE

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

It is very important that you read the Patient Information for abarelix before you start …

Related articles from newspapers, magazines, journals, and more
Abarelix (Systemic).(Drug overview)
USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language May 1, 2006 700+ words
Abarelix (Systemic).
USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language October 27, 2005 700+ words
Public summary of opinion on orphan designation: Abarelix for the treatment...
News wire article from: Chemical Business Newsbase October 18, 2010 700+ words
UCB-Bioproducts opens peptides production unit in S Carolina.
News wire article from: Asia Africa Intelligence Wire March 10, 2003 700+ words
PRAECIS PHARMACEUTICALS INC. / Cambridge, Mass. Company's Hopes High For New...
Magazine article from: Investor's Business Daily September 18, 2000 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily